UCI Health | Strategic Alliance Partners

August 13, 2021

The majority of patients with newly diagnosed chronic lymphocytic leukemia have better outcomes with BTK inhibitors compared with standard chemoimmunotherapy, making them the logical choice for frontline therapy.

June 18, 2019

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses the FDA approval of pembrolizumab (Keytruda) in small cell lung cancer (SCLC).

June 07, 2019

Sai-Hong I. Ou, MD, PhD, professor, Division of Hematology/Oncology, Department of Medicine, University of California Irvine School of Medicine, discusses investigational KRAS inhibitors in lung cancer.

May 23, 2019

Sai-Hong I. Ou, MD, PhD, discusses the status of different mutations in lung cancer and the work being done to bring clinically meaningful treatments to the space.

May 22, 2019

Sai-Hong I. Ou, MD, highlights the conveniences of liquid biopsies relative to tissue biopsies, as well as current drawbacks to their use in detecting targetable alterations in lung cancer.

March 29, 2019

The frontline combination of fulvestrant and anastrozole resulted in a sustained benefit in progression-free survival and a significant improvement in overall survival compared with anastrozole alone in patients with postmenopausal, HR–positive metastatic breast cancer, according to long-term results of the SWOG S0226 trial.

August 10, 2018

Susan M. O'Brien, MD, discusses some of the latest intriguing data in the treatment of chronic lymphocytic leukemia and what this means for physicians and patients.

May 05, 2018

Sai-Hong I. Ou, MD, professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, discusses the use of crizotinib (Xalkori) in the treatment of patients with ROS1-rearranged non–small cell lung cancer (NSCLC).

January 20, 2017

It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.

August 11, 2016

Susan M. O'Brien, MD, associate director for Clinical Science for the Chao Family Comprehensive Cancer Center, medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses how ibrutinib (Imbruvica) compares with chemoimmunotherapy as a frontline treatment for patients with chronic lymphocytic leukemia.

June 01, 2016

Susan M. O'Brien, MD, discusses upcoming novel treatments in relapsed/refractory chronic lymphocytic leukemia, such as the next generation of inhibition with BTK, SYK, and PI3K, as well as the outcomes of the recent RESONATE-2 trial.

August 26, 2015

Susan M. O'Brien, MD, discusses the impact and the future outlook for idelalisib and ibrutinib in chronic lymphocytic leukemia.

September 16, 2014

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.